Table 1.
Demographic and cancer characteristics of COVID-19 positive and negative cancer patients.
| Variable | Total (n = 2152) |
COVID-19 Status | ||||
|---|---|---|---|---|---|---|
| Positive (n = 190) |
Negative (n = 1962) |
|||||
| n | % | n | % | n | % | |
| Sex | ||||||
| Male | 969 | 45.00 | 112 | 58.90 | 857 | 43.70 |
| Female | 1183 | 55.00 | 78 | 41.10 | 1105 | 56.30 |
| Age | ||||||
| <50 | 362 | 16.80 | 30 | 15.80 | 332 | 16.90 |
| 50–59 | 503 | 23.40 | 36 | 18.90 | 467 | 23.80 |
| 60–69 | 613 | 28.50 | 55 | 28.90 | 558 | 28.40 |
| 70–79 | 476 | 22.10 | 40 | 21.10 | 436 | 22.20 |
| ≥80 | 198 | 9.20 | 29 | 15.30 | 169 | 8.60 |
| Mean (SD) | 62.60 (13.30) | 63.80 (14.80) | 62.50 (13.20) | |||
| SES | ||||||
| Low | 1848 | 85.90 | 157 | 82.60 | 1691 | 86.20 |
| Medium | 36 | 1.70 | 0 | 0.00 | 36 | 1.80 |
| High | 150 | 7.00 | 19 | 10.00 | 131 | 6.70 |
| Missing | 118 | 5.50 | 14 | 7.40 | 104 | 5.30 |
| Ethnicity | ||||||
| White British | 923 | 42.90 | 84 | 44.20 | 839 | 42.80 |
| White Other | 196 | 9.10 | 14 | 7.40 | 182 | 9.30 |
| Black Caribbean | 89 | 4.10 | 10 | 5.30 | 79 | 4.00 |
| Black African | 102 | 4.70 | 17 | 8.90 | 85 | 4.30 |
| Black Other | 78 | 3.60 | 15 | 7.90 | 63 | 3.20 |
| Asian | 62 | 2.90 | 7 | 3.70 | 55 | 2.80 |
| Mixed | 25 | 1.20 | 2 | 1.10 | 23 | 1.20 |
| Other | 43 | 2.00 | 4 | 2.10 | 39 | 2.00 |
| Unknown | 634 | 29.50 | 37 | 19.50 | 597 | 30.40 |
| Smoking history | ||||||
| Never | 563 | 26.20 | 66 | 34.70 | 497 | 25.30 |
| Current | 206 | 9.60 | 19 | 10.00 | 187 | 9.50 |
| Ex-smoker | 432 | 20.10 | 48 | 25.30 | 384 | 19.60 |
| Unknown | 951 | 44.20 | 57 | 30.00 | 894 | 45.60 |
| Cancer type | ||||||
| Urological | 320 | 14.90 | 41 | 21.50 | 279 | 14.20 |
| Gynaecological | 226 | 10.50 | 10 | 5.30 | 216 | 11.00 |
| Gastro-intestinal | 395 | 18.40 | 29 | 15.30 | 366 | 18.70 |
| Skin/Head & neck | 199 | 9.20 | 16 | 8.40 | 183 | 9.30 |
| Central Nervous System | 39 | 1.80 | 12 | 6.30 | 27 | 1.40 |
| Breast | 456 | 21.20 | 27 | 14.20 | 429 | 21.90 |
| Lung | 300 | 13.90 | 22 | 11.60 | 278 | 14.20 |
| Haematological | 195 | 9.10 | 33 | 17.40 | 162 | 8.30 |
| Other | 22 | 1.00 | 0 | 0.00 | 22 | 1.10 |
| Cancer stage | ||||||
| I | 233 | 10.80 | 21 | 11.10 | 212 | 10.80 |
| II | 304 | 14.10 | 34 | 17.90 | 270 | 13.80 |
| III | 450 | 20.90 | 34 | 17.90 | 416 | 21.20 |
| IV | 889 | 41.30 | 76 | 40.00 | 813 | 41.40 |
| Missing | 276 | 12.80 | 25 | 13.20 | 251 | 12.80 |
| Treatment Paradigm | ||||||
| Treatment naive | 56 | 2.60 | 18 | 9.50 | 38 | 1.90 |
| Neoadjuvant | 117 | 5.40 | 10 | 5.30 | 107 | 5.50 |
| Adjuvant | 419 | 19.50 | 12 | 6.30 | 407 | 20.70 |
| Radical | 388 | 18.00 | 49 | 25.80 | 339 | 17.30 |
| Palliative | 970 | 45.10 | 78 | 41.10 | 892 | 45.50 |
| Watch and wait | 96 | 4.50 | 18 | 9.50 | 78 | 4.00 |
| Missing | 106 | 4.90 | 5 | 2.60 | 101 | 5.10 |
| Line of Palliative Treatment (n = 970) | ||||||
| 1 | 370 | 38.60 | 38 | 50.70 | 332 | 37.60 |
| 2 | 243 | 25.40 | 22 | 29.30 | 221 | 25.00 |
| 3 | 108 | 11.30 | 7 | 9.30 | 101 | 11.40 |
| >4 | 53 | 5.60 | 1 | 1.30 | 52 | 5.90 |
| Missing | 196 | 20.20 | 10 | 12.80 | 186 | 20.90 |
| Systemic Treatment (n = 1448) | ||||||
| Chemotherapy | 708 | 48.90 | 65 | 61.90 | 643 | 47.90 |
| Immunotherapy | 110 | 7.00 | 9 | 8.60 | 101 | 7.50 |
| Biological | 163 | 11.30 | 14 | 13.30 | 149 | 11.10 |
| Targeted Therapy | 202 | 14.00 | 6 | 5.70 | 196 | 14.60 |
| Combination Therapy | 265 | 18.30 | 11 | 10.50 | 254 | 18.90 |
| Time since cancer diagnosis | ||||||
| <1 year | 974 | 45.30 | 96 | 50.50 | 878 | 44.80 |
| 1–2 years | 340 | 15.80 | 23 | 12.10 | 317 | 16.20 |
| 2–5 years | 399 | 18.50 | 29 | 15.30 | 370 | 18.90 |
| ≥5 years | 323 | 15.00 | 36 | 18.90 | 287 | 14.60 |
| Missing | 116 | 5.40 | 6 | 3.20 | 110 | 5.60 |